Imagion Biosystems Limited (IBXXF)

Market Cap	6.88M +199.1%
Revenue (ttm)	48.71K -97.3%
Net Income	-2.87M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	54,967
Open	0.0150
Previous Close	n/a
Day's Range	0.0150 - 0.0150
52-Week Range	0.0080 - 0.0300
Beta	-0.16
RSI	44.42
Earnings Date	Feb 26, 2026

About Imagion Biosystems

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has collaboration with Siemens MRI to support the Phase 2 study of MagSense HER2 imaging agent...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: IBXXF

Financial Performance

In 2025, Imagion Biosystems's revenue was 73,031, a decrease of -97.26% compared to the previous year's 2.67 million. Losses were -4.31 million, 108.5% more than in 2024.

Financial numbers in AUD